Oral available agents in the treatment of RRMS

Oral available agents in the treatment of RRMS

Thierry Aupérin Medical Communications, Global MS Medical Affairs, Genzyme Corporation, Cambridge, MA, USAWe read with interest the article by Drs Thöne and Ellrichmann entitled "Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of...

Full description

Bibliographic Details
Main Author:	Aup&eacute;rin T
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-10-01
Series:	Drug, Healthcare and Patient Safety
Online Access:	http://www.dovepress.com/oral-available-agents-in-the-treatment-of-rrms-a14818

Similar Items

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
by: Tjalf Ziemssen, et al.
Published: (2017-08-01)

Oral available agents in the treatment of relapsing remitting multiple sclerosis an overview of merits and culprits
by: Th&ouml;ne J, et al.
Published: (2013-02-01)

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
by: Lesage, E, et al.
Published: (2010)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
by: Martin Vališ, et al.
Published: (2020-05-01)

Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study
by: Minodora Dobreanu, et al.
Published: (2021-12-01)

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients
by: Tjalf Ziemssen, et al.
Published: (2021-03-01)

SwissTecLive: effectiveness and safety of dimethyl fumarate in the treatment of RRMS in the Swiss clinical practice setting
by: Chiara Zecca, et al.
Published: (2020-12-01)

Cytokine Secretion Dynamics of Isolated PBMC after Cladribine Exposure in RRMS Patients
by: Rodica Balasa, et al.
Published: (2022-09-01)

010 Real-world experience with ocrelizumab in the MSBase registry – Australian RRMS cohort
by: Mark Slee, et al.
Published: (2021-08-01)

Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS)
by: Silvia Ciotti, et al.
Published: (2021-02-01)

Structural brain network characteristics can differentiate CIS from early RRMS
by: Muthuraman eMuthuraman, et al.
Published: (2016-02-01)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
by: Feng J, et al.
Published: (2019-11-01)

EDSS and infratentorial white matter lesion volume are considered predictors of fatigue severity in RRMS
by: Mohammed Y. Ezzeldin, et al.
Published: (2023-07-01)

Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis
by: Naresh Mutukula, et al.
Published: (2021-05-01)

Increased Level of Caspase-1 in the Serum of Relapsing-remitting Multiple Sclerosis (RRMS) Patients
by: Masoumeh Beheshti, et al.
Published: (2020-10-01)

Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?
by: Jan-Patrick Stellmann, et al.
Published: (2015-01-01)

Assessing retro-reflective markers (RRMs) usage on heavy vehicles with respect to MS 828:2011
by: Mohd Amirudin M.R, et al.
Published: (2017-01-01)

Studying the Expression of SNX2 (Sorting nexin-2) in Patients with RRMS Compared with Health Control
by: Fariba Bani Talebi Dehkordi, et al.
Published: (2017-06-01)

A Comparison of IgG Index and Oligoclonal Band in the Cerebrospinal Fluid for Differentiating between RRMS and NMOSD
by: Bo Chen, et al.
Published: (2021-12-01)

Reduced Expression of PD-1 in Circulating CD4+ and CD8+ Tregs Is an Early Feature of RRMS
by: Maja Machcińska, et al.
Published: (2022-03-01)

IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study
by: Zhengjuan Lu, et al.
Published: (2020-09-01)

Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
by: Guilherme Silva Julian, et al.
Published: (2020-01-01)

The Comparison of the Selected Parameters of Brain Injury and Interleukins in the CSF in Patients Diagnosed De Novo with RRMS Compared to the Control Group
by: Bożena Adamczyk, et al.
Published: (2023-11-01)

Down-Regulation Smurf2 (Smad ubiquitin Regulatory Factor 2) Gene in Patients With RRMS and Association With High Disability
by: F Behdarvand Dehkordi, et al.
Published: (2018-11-01)

Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA—A Preliminary Study
by: María Paulina Reyes-Mata, et al.
Published: (2023-05-01)

Serum and CSF Biomarkers Predict Active Early Cognitive Decline Rather Than Established Cognitive Impairment at the Moment of RRMS Diagnosis
by: Vlad Eugen Tiu, et al.
Published: (2022-10-01)

Preparation, characterization and in-vivo efficacy study of glatiramer acetate (GA)-hydrogel-microparticles as novel drug delivery system for GA in RRMS
by: Naghmeh Hadidi, et al.
Published: (2022-12-01)

Single-Cell Transcriptome Profiling Unravels Distinct Peripheral Blood Immune Cell Signatures of RRMS and MOG Antibody-Associated Disease
by: Ju Liu, et al.
Published: (2022-01-01)

Evaluation of the Effect and Drug Side Effects of Fingolimod in the 3-Year Follow-up of Patients with Recurrent Form of Multiple Sclerosis (RRMS)
by: N Razazian, et al.
Published: (2020-04-01)

The TOTEM RRMS (Testosterone Treatment on neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis) trial: study protocol for a randomized, double-blind, placebo-controlled trial
by: Katline Metzger-Peter, et al.
Published: (2020-06-01)

DISABILITY PROGRESSION IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) WHO EXPERIENCE DISEASE ACTIVITY DESPITE PREVIOUS DISEASE MODIFYING THERAPY
by: Hettle, R, et al.
Published: (2011)

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.
by: Tamás Biernacki, et al.
Published: (2022-01-01)

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
by: C&eacute;sar Bustos, et al.
Published: (2010-04-01)

Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy
by: St&eacute;phane Auvin
Published: (2007-01-01)

Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole
by: Bruno M&eacute;garbane
Published: (2010-08-01)

The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients
by: Rozhin Dabbaghi, et al.
Published: (2023-10-01)

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
by: Jos&eacute; Luis Callejas-Rubio, et al.
Published: (2008-12-01)

Blood Metabolomics May Discriminate a Sub-Group of Patients with First Demyelinating Episode in the Context of RRMS with Increased Disability and MRI Characteristics Indicative of Poor Prognosis
by: Marina Boziki, et al.
Published: (2022-11-01)

Long-term follow up of interferon-beta-1b pivotal trial RRMS patients: design issues of a 16-year follow-up study
by: Ebers, G, et al.
Published: (2004)

The Availability and Provision of a Reversal Agent for an Oral Anticoagulant and its Impact on the National Health Service
by: Luís Silva Miguel, et al.
Published: (2017-01-01)